- Home
- VRAX vs SBFM Comparison
VRAX vs SBFM Comparison
Compare VRAX & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- SBFM
- Stock Information
- Founded
- VRAX 2013
- SBFM 2006
- Country
- VRAX United Kingdom
- SBFM United States
- Employees
- VRAX N/A
- SBFM N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- SBFM Health Care
- Exchange
- VRAX Nasdaq
- SBFM Nasdaq
- Market Cap
- VRAX 7.3M
- SBFM 6.8M
- IPO Year
- VRAX 2022
- SBFM N/A
- Fundamental
- Price
- VRAX $1.87
- SBFM $2.45
- Analyst Decision
- VRAX
- SBFM Strong Buy
- Analyst Count
- VRAX 0
- SBFM 1
- Target Price
- VRAX N/A
- SBFM $15.00
- AVG Volume (30 Days)
- VRAX 304.3K
- SBFM 52.5K
- Earning Date
- VRAX 02-05-2025
- SBFM 03-27-2025
- Dividend Yield
- VRAX N/A
- SBFM N/A
- EPS Growth
- VRAX N/A
- SBFM N/A
- EPS
- VRAX N/A
- SBFM N/A
- Revenue
- VRAX $84,872.00
- SBFM $32,959,491.00
- Revenue This Year
- VRAX $5,169.18
- SBFM $59.94
- Revenue Next Year
- VRAX $66.97
- SBFM $164.69
- P/E Ratio
- VRAX N/A
- SBFM N/A
- Revenue Growth
- VRAX 7.03
- SBFM 61.94
- 52 Week Low
- VRAX $0.60
- SBFM $2.11
- 52 Week High
- VRAX $9.00
- SBFM $286.00
- Technical
- Relative Strength Index (RSI)
- VRAX 48.66
- SBFM 38.35
- Support Level
- VRAX $1.65
- SBFM $2.39
- Resistance Level
- VRAX $2.10
- SBFM $2.58
- Average True Range (ATR)
- VRAX 0.22
- SBFM 0.15
- MACD
- VRAX 0.01
- SBFM -0.01
- Stochastic Oscillator
- VRAX 42.47
- SBFM 14.89
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.